**Video Post** MedTech Study: NGL & UCLA Biodesign

Complex regulation, cost containment, enterprise risk, uncertain revenue proposition. These are just some of the factors that hinder healthcare innovation. Now, add on top of that, the fact that so many innovations come from individuals outside of the particular industry in which that innovation is meant to “breakthrough.”

The UCLA Biodesign Hub for MedTech and Digital Health (UCLA Biodesign) is seeking executives from medical technology and digital health companies to participate in a new study focused on advancing regulatory infrastructure and reimbursement for innovative technologies. This study aims to establish benchmarks, educate regulators, and influence future healthcare policy at a state and national level. UCLA Biodesign invites founders and executives at med tech and digital health companies to participate in its landmark study, Innovation in MedTech and Digital Health: A New Decade!

For more information on this study and how it could benefit your company, please watch this short video:

Learn more here!

  • Faisal Khan, Esq., Senior Counsel, Nixon Gwilt Law

  • Jennifer McCaney, Ph.D., Co-Executive Director of UCLA Biodesign, former Director of MedTech Innovator

  • Kwame Ulmer, MBA, Venture Partner at Wavemaker Three-Sixty Health and the Principal at Ulmer Ventures, former FDA Deputy Director and Branch Chief

  • Christian Johnson, MBA, MS, Fellow, UCLA Biodesign

If you have questions, email info@medtechstudy.com, or Christian at christian@medtechstudy.com.

Digital Therapeutics/SaMDNixon Law GroupUCLA biodesign, medical technology, digital health, research, study, innovation, medtech